现实世界NUDT15基因型定制和在炎症性肠病中优化滴氨酸治疗:一项多中心研究
Motoki Makuuchi1, Yoichi Kakuta2, Junji Umeno3
1Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai, 980-8574, Japan.
Journal of gastroenterology
|April 8, 2024
概括
通过减少不良事件和改善治疗保留,NUDT15基因型定型优化了炎症性肠病 (IBD) 患者的提奥普林治疗. 基因型引导调整导致更安全,更有效的IBD管理.
科学领域:
- 药物基因组学 药物基因组学
- 胃肠病学 胃肠病学
- 临床医学 临床医学
背景情况:
- 提奥普林药物对于炎症性肠病 (IBD) 管理至关重要.
- 遗传变异,特别是在NUDT15中,会影响氨酸药物代谢和毒性.
- 优化硫氨酸治疗需要基于遗传特征的个性化方法.
研究的目的:
- 评估NUDT15编码139基因定型在优化日本IBD患者的提奥普林治疗中的有效性.
- 建立基于基因型的治疗策略,用于IBD中的提奥普林治疗.
- 分析NUDT15基因定型对提奥普林处方和患者结局的影响的现实数据.
主要方法:
- 对4628名接受NUDT15 codon 139基因定型的IBD患者进行了回顾性分析.
- 与 (基因型化组) 和没有 (非基因型化组) 基因型化治疗西奥普林的患者之间的结局比较.
- 基于基因型和基因型化状态的不良事件 (AE) 风险因素分析.
主要成果:
- NUDT15基因型定型引导剂量调整,导致Arg/Cys患者的不良事件发生率降低.
- 在Arg/Arg患者中,初始用量较高的蒂奥普林,而在Arg/Cys患者中,初始用量较低 (平均25毫克/天).
- 基于基因型的剂量调整改善了治疗的持续时间,并减少了副作用,特别是恶心和肝损伤,这与配方相关.
结论:
- NUDT15编码子139基因定型有效地减少了氨酸诱导的副作用,并改善了IBD患者的治疗保留率.
- 基于基因型的剂量调整使得提奥普林治疗方法更加精细和个性化.
- 这项研究提供了基于数据的策略,以优化基于NUDT15基因型的提奥普林治疗.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116


